Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Verily, IBM, litigation funder on the art of leveraging patents
Americas
Verily, IBM, litigation funder on the art of leveraging patents
Companies are transforming IP from a defensive tool into a revenue-generating powerhouse. Marisa Woutersen at the WIPR Summit 2025 hears trends in licensing, platform-based monetisation, and litigation funding.   18 March 2025
Trouble at the USPTO—Part II: Bracing for impact
Americas
Trouble at the USPTO—Part II: Bracing for impact
As IP professionals wait for agency cutbacks to be felt down the chain, the advice is to stay informed, manage budgets wisely, and use a mix of protections to weather any disruption, finds Marisa Woutersen.   13 March 2025
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
Return-to-office orders, redundancies, hiring freezes—do changes sweeping through the US agency ‘risk breaking the system’? Marisa Woutersen finds patent practitioners fearful of the future.   6 March 2025
Americas
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.   6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
Based in Silicon Valley and San Francisco, the duo bring experience in patent litigation across life sciences, biotechnology, and high technology, including a recent victory overturning a $96 million jury verdict in an organ transplant testing case.   4 March 2025
Europe
La Prairie accused of stealing caviar biotech for luxury skincare line
UK biotech firm accuses luxury skincare brand La Prairie of misappropriating proprietary research on caviar-derived ingredients | Lawsuit claims La Prairie lacked expertise to develop the tech before accessing confidential trade secrets.   4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
Top contenders named across 20 categories including litigation, prosecution and portfolio management | Nominees include Dechert, Desmarais, Fish & Richardson, Irell & Manella, Sterne Kessler, Mintz, Wilson Sonsini, Banner Witcoff, and Powell Gilbert.   3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.   27 February 2025
Americas
Paul Hastings adds Latham tech transactions expert as co-chair
Former Latham & Watkins global vice chair joins the firm as co-chair of its technology transactions practice | New partner brings experience in biotechnology, life sciences, technology, artificial intelligence and sustainable energy.   27 February 2025
Europe
Why Abbott’s victory marks a turning point for UPC preliminary injunctions
The company’s nine-country ban against a Chinese rival saw the court adopt a broad interpretation of means-plus-function claims, increasing the risk for infringers even if they modify products. Marisa Woutersen unpacks the debate over the UPC’s flexible approach to added matter and the urgency criteria.   25 February 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.